Roche, Xenon ink $646 million pain pact

Friday, January 13, 2012 12:15 PM

Roche’s Genentech unit plans to discover compounds and diagnostics for treatment of pain by collaborating with Xenon Pharmaceuticals, based in Vancouver.

Xenon will receive an undisclosed upfront payment from Genentech, as well as research funding. Xenon has the possibility of receiving additional R&D commercialization milestone payments of up to $646 million, plus royalties. In return, Genentech will have an exclusive license to compounds and a non-exclusive right to any diagnostics.

This alliance is Xenon’s sixth partnership with a major pharmaceutical company, including Merck, Takeda and Novartis.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs